Wall Street analyst estimates for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Valuation Ratios
| P/E Ratio | 55.22 |
| Price / Book | 1.58 |
| EV / EBITDA | -99.55 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Research & Development | 0 | 0 |
| Selling, General & Admin | $480 | $2.8M |
| Operating Expenses | $480 | $2.8M |
| Operating Income | -$479 | -$2.8M |
| EBITDA | -$279845 | -$2.8M |
| Interest Expense | 0 | 0 |
| Pre-tax Income | -$479 | $5.9M |
| Income Tax | 0 | 0 |
| Net Income | -$479 | $5.9M |
| EPS | $-0.06 | $0.19 |
| EPS (Diluted) | $-0.06 | $0.19 |
| Shares Outstanding (Diluted) | $8.6M | $21.0M |
Price
| Price | $10.84 |
| Market Cap | $263M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALF · LOKV · MLAC · OYSE · RTAC · SIMA · TACH
Explore sector: Financial Services · Shell Companies
More sections of DMAA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks